A detailed history of Bank Of America Corp transactions in Sana Biotechnology, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 910,167 shares of SANA stock, worth $2.74 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
910,167
Previous 548,027 66.08%
Holding current value
$2.74 Million
Previous $5.48 Million 9.32%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$5.23 - $10.44 $1.89 Million - $3.78 Million
362,140 Added 66.08%
910,167 $4.97 Million
Q1 2024

May 15, 2024

BUY
$4.2 - $11.27 $278,195 - $746,490
66,237 Added 13.75%
548,027 $5.48 Million
Q4 2023

Feb 14, 2024

BUY
$2.8 - $4.55 $287,137 - $466,597
102,549 Added 27.04%
481,790 $1.97 Million
Q2 2023

Aug 14, 2023

SELL
$3.22 - $7.53 $976,271 - $2.28 Million
-303,190 Reduced 44.43%
379,241 $2.26 Million
Q1 2023

May 12, 2023

BUY
$3.11 - $4.92 $46,180 - $73,057
14,849 Added 2.22%
682,431 $2.23 Million
Q4 2022

Feb 10, 2023

BUY
$3.19 - $6.46 $666,607 - $1.35 Million
208,968 Added 45.57%
667,582 $2.64 Million
Q3 2022

Nov 14, 2022

BUY
$5.58 - $9.04 $524,045 - $848,991
93,915 Added 25.75%
458,614 $2.75 Million
Q2 2022

Aug 12, 2022

SELL
$4.12 - $9.35 $61,338 - $139,202
-14,888 Reduced 3.92%
364,699 $2.35 Million
Q1 2022

May 16, 2022

BUY
$5.24 - $15.58 $1.7 Million - $5.06 Million
324,866 Added 593.68%
379,587 $3.14 Million
Q4 2021

Feb 08, 2022

BUY
$15.18 - $23.15 $659,737 - $1.01 Million
43,461 Added 385.98%
54,721 $847,000
Q3 2021

Nov 15, 2021

SELL
$16.29 - $25.88 $16,420 - $26,087
-1,008 Reduced 8.22%
11,260 $254,000
Q2 2021

Sep 13, 2021

BUY
$16.65 - $32.14 $204,262 - $394,293
12,268 New
12,268 $241,000

Others Institutions Holding SANA

About Sana Biotechnology, Inc.


  • Ticker SANA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 190,232,000
  • Market Cap $573M
  • Description
  • Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others...
More about SANA
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.